Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Boston Children's Hospital
Headquarters: Boston, MA, United States of America
Website: http://www.childrenshospital...
Year Founded: 1869
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Dec 16, 2024
Distillery Therapeutics
Universal GATA1 gene therapy for Diamond-Blackfan anemia
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Mar 27, 2024
Emerging Company Profile
Latigo: aiming for best-in-class non-opioid analgesia via Nav1.8
Ex-Amgen executives reunite for CNS company incubated by Westlake and backed with $135M
BioCentury | Feb 17, 2024
Discovery & Translation
Science spotlight: a germinal center B cell-activating adjuvant, peptide-conjugated CARs and more
BioCentury’s roundup of translational innovations
BioCentury | Jan 20, 2024
Discovery & Translation
Omics points to drivers of myeloid cancer, long COVID; plus ILC2 cell therapies and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 1, 2023
Regulation
Exa-cel meeting clarifies off-target expectations for gene editing therapies
FDA’s advisers were satisfied with the methods used by CRISPR Therapeutics and Vertex to analyze the off-target edits of gene editing therapy exa-cel
BioCentury | Sep 28, 2023
Regulation
Panel finds NurOwn data far below standards of recent ALS approvals
FDA panel overwhelmingly votes against BrainStorm therapy
BioCentury | Sep 5, 2023
Discovery & Translation
Epitope editing of immunotherapies; plus NovoBiotic’s antibiotic and more
BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 191